-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Osalmid
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/526-18-1.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 526-18-1 |
| Description | Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound that suppresses RRM2 activity in a concentration-dependent manner. |
Product Information
| Synonyms | Oxaphenamide; Osalmide |
| IUPAC Name | 2-hydroxy-N-(4-hydroxyphenyl)benzamide |
| Molecular Weight | 229.23 |
| Molecular Formula | C13H11NO3 |
| Canonical SMILES | C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)O)O |
| InChI | InChI=1S/C13H11NO3/c15-10-7-5-9(6-8-10)14-13(17)11-3-1-2-4-12(11)16/h1-8,15-16H,(H,14,17) |
| InChIKey | LGCMKPRGGJRYGM-UHFFFAOYSA-N |
| Boiling Point | 350.8±27.0 °C at 760 mmHg |
| Melting Point | 179°C |
| Flash Point | 165.9±23.7 °C |
| Purity | 99.85% |
| Density | 1.4±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 261 |
| Exact Mass | 229.07389321 |
| Index Of Refraction | 1.711 |
| In Vitro | Osalmid is identified as a potential ribonucleotide reductase small subunit M2 (RRM2) compound. Osalmid is 10-fold more active in inhibiting ribonucleotide reductase (RR) activity than hydroxyurea, and significantly inhibits HBV DNA and cccDNA synthesis in HepG2.2.15 cells in a time- and dose-dependent manner. After treatment for 8 days with Osalmid, the EC50 for HBV DNA inhibition are 11.1 μM for culture supernatant and 16.5 μM for cells. Osalmid suppresses RR activity in a concentration-dependent manner, with an IC50 of 8.23 μM. Osalmid is shown to possess potent activity against a 3TC-resistant HBV strain, suggesting utility in treating drug-resistant HBV infections. |
| In Vivo | Osalmid reduces RR activity and HBV replication in HBV-transgenic mice and shows a synergistic efficacy with 3TC without significant toxicity. Oral dosing of osalmid at 400 mg/kg/d results in a time-dependent inhibition of HBV DNA replication. After treatment for 4 weeks, osalmid suppresses HBV DNA replication by about 40-45% as compared to the control in mouse sera and liver tissues. |
| PSA | 69.56000 |
| Target | IC50: 8.23 μM (ribonucleotide reductase) |
| Vapor Pressure | 0.0±0.8 mmHg at 25°C |
| XLogP3-AA | 2.9 |
